This special episode of the "Nervennahrung" podcast serves as an introduction to the new co-host, Professor Tobias Ruck, who will be replacing Professor Sven Meut. The current host, Professor Matthias Meurer, interviews Ruck about his professional background, clinical focus, and motivations for joining the podcast. Ruck, now the Director of Neurology at Bergmannsheil in Bochum, details his career path from his studies in Würzburg to his work alongside the departing host in Münster and Düsseldorf. His primary clinical and research interests are in neuroimmunology and peripheral nervous system disorders, particularly Myasthenia Gravis, Myositis, and hereditary neuropathies. The conversation also explores the future of neurology, touching on the transformative potential of gene therapies, the recent approval of Lecanemab for Alzheimer's disease, and the role of artificial intelligence in shaping the specialty.
Introducing the New Host and Discussing the Future of Neurology
00:00:12 - Change in the Host Team: Host Matthias Meurer announces that Professor Sven Meut is stepping down from the podcast due to his duties with the German Society for Neurology. He introduces Professor Tobias Ruck as the new co-host.
00:00:58 - Professor Tobias Ruck's Background: Ruck is the Director of Neurology at Bergmannsheil in Bochum and was previously the deputy to Sven Meut at the University Hospital Düsseldorf, making his succession a logical step.
00:02:59 - Academic and Professional Journey: Ruck recounts his path, starting with medical studies in Würzburg, where his interest in both neurology and immunology began. This led him to work with and follow Sven Meut and Heinz Wiendl from Würzburg to Münster.
00:05:37 - Clinical and Research Focus: Ruck’s main areas of expertise are in the peripheral nervous system, specifically Myasthenia Gravis, Myositis, and inflammatory neuropathies. He is also deeply involved in the treatment of hereditary neuromuscular diseases.
00:06:17 - Advancements in Gene Therapy: He highlights the revolutionary progress in vector-based gene therapies for hereditary conditions like Charcot-Marie-Tooth disease, noting the field is shifting from mere diagnosis to providing effective treatments.
00:09:47 - The Future of Neurology and AI: Ruck believes that while neurology will become increasingly specialized, it's crucial to maintain a holistic perspective. He sees Artificial Intelligence (AI) as a key tool for assisting in diagnosis and monitoring, which could free up clinicians' time for patient care rather than administrative tasks.
00:11:47 - Perspective on Lecanemab: Ruck considers the recent approval of Lecanemab for Alzheimer's disease a significant first step, despite its modest effects. He acknowledges it will create a major logistical challenge for clinics due to high patient interest and the need to identify the narrow group of suitable candidates.
00:15:07 - Personal Interests: Outside of neurology, Ruck is a father to two young children and enjoys playing tennis and going to the theater.